Document:

Exhibit 10.1

 

UNITED STATES OF AMERICA

BEFORE THE

BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM

WASHINGTON, D.C.

 

Written
Agreement by and between

Docket No. 10-146-WA/RB-HC

COMMUNITY
VALLEY BANCORP

Chico,
California

 

and

 

FEDERAL
RESERVE BANK

OF
SAN FRANCISCO

San
Francisco, California

 

WHEREAS,
Community Valley Bancorp, Chico, California (“Community Valley”), a registered
bank holding company, owns and controls Butte Community Bank, Chico, California
(the “Bank”), a state-chartered nonmember bank, and various nonbank
subsidiaries;

 

WHEREAS,
it is the common goal of Community Valley and the Federal Reserve Bank of San
Francisco (the “Reserve Bank”) to maintain the financial soundness of Community
Valley so that Community Valley may serve as a source of strength to the Bank;

 

WHEREAS,
Community Valley and the Reserve Bank have mutually agreed to enter into this
Written Agreement (the “Agreement”); and

 

WHEREAS,
on July 20, 2010, the board of directors of Community Valley, at a duly
constituted meeting, adopted a resolution authorizing and directing John F.
Coger to enter into this Agreement on behalf of Community Valley, and
consenting to compliance with each and every provision of this Agreement by
Community Valley and its institution-affiliated parties, as defined in sections
3(u) and 8(b)(3) of the Federal Deposit Insurance Act, as amended (the “FDI Act”)
(12 U.S.C. §§ 1813(u) and 1818(b)(3)).

 

 

NOW,
THEREFORE, Community Valley and the Reserve Bank agree as follows:

 

Source
of Strength

 

1.
            The board of directors
of Community Valley shall take appropriate steps to fully utilize Community
Valley’s financial and managerial resources, pursuant to Section 225.4 (a) of
Regulation Y of the Board of Governors of the Federal Reserve System (the “Board
of Governors”) (12 C.F.R. § 225.4(a)), to serve as a source of strength to the
Bank, including, but not limited to, taking steps to ensure that the Bank
complies with the Consent Order entered into with the Federal Deposit Insurance
Corporation (the “FDIC”) and the California Department of Financial
Institutions on May 11, 2010, and any other supervisory action taken by the
Bank’s federal or state regulator.

 

Dividends
and Distributions

 

2.
            (a)     Community Valley shall not declare or pay
any dividends without the prior written approval of the Reserve Bank and the
Director of the Division of Banking Supervision and Regulation (the “Director”)
of the Board of Governors of the Federal Reserve System (the “Board of
Governors”).

 

(b)     Community Valley shall not directly or
indirectly take dividends or any other form of payment representing a reduction
in capital from the Bank without the prior written approval of the Reserve
Bank.

 

(c)     Community Valley and its nonbank
subsidiaries shall not make any distributions of interest, principal, or other
sums on subordinated debentures or trust preferred securities without the prior
written approval of the Reserve Bank and the Director.

 

(d)     All requests for prior approval shall be
received by the Reserve Bank at least 30 days prior to the proposed dividend
declaration date, proposed distribution on subordinated debentures, and
required notice of deferral on trust preferred securities. All requests shall
contain, at a minimum, current and projected information on Community Valley’s
capital, earnings, and cash flow; the Bank’s capital, asset quality, earnings,
and allowance for loan and lease losses (the “ALLL”); and identification of the
sources of funds for the proposed payment or distribution. For requests to
declare or pay dividends, Community Valley must also demonstrate that the
requested declaration or payment of dividends is consistent with the Board of
Governors’ Policy Statement on the Payment of Cash Dividends by State Member
Banks and Bank Holding Companies, dated November 14, 1985 (Federal Reserve
Regulatory Service, 4-877 at page 4-323).

 

Debt
and Stock Redemption

 

3.
            (a)     Community Valley and any nonbank
subsidiary shall not, directly or indirectly, incur, increase, or guarantee any
debt without the prior written approval of the Reserve Bank. All requests for
prior written approval shall contain, but not be limited to, a statement
regarding the purpose of the debt, the terms of the debt, and the planned
source(s) for 

 

 

debt
repayment, and an analysis of the cash flow resources available to meet such
debt repayment.

 

(b)     Community Valley shall not, directly or
indirectly, purchase or redeem any shares of its stock without the prior
written approval of the Reserve Bank.

 

Capital
Plan

 

4.
            Within 45 days of
this Agreement, Community Valley shall submit to the Reserve Bank an acceptable
written plan to maintain sufficient capital at Community Valley on a
consolidated basis. The plan shall, at a minimum, address, consider, and
include:

 

(a)     The consolidated organization’s and the
Bank’s current and future capital requirements, including compliance with the
Capital Adequacy Guidelines for Bank Holding Companies: Risk-Based Measure and
Tier 1 Leverage Measure, Appendices A and D of Regulation Y of the Board of
Governors (12 C.F.R. Part 225, App. A and D) and the applicable capital
adequacy guidelines for the Bank issued by the FDIC;

 

(b)     the adequacy of the Bank’s capital, taking
into account the volume of classified credits, concentrations of credit, ALLL,
current and projected asset growth, and projected retained earnings;

 

(c)     the source and timing of additional funds
necessary to fulfill the consolidated organization’s and the Bank’s future
capital requirements;

 

(d)     supervisory requests for additional
capital at the Bank or the requirements of any supervisory action imposed on
the Bank by the FDIC; and

 

(e)     the requirements of section 225.4(a) of
Regulation Y of the Board of Governors (12 C.F.R. § 225.4(a)) that Community
Valley serve as a source of strength to the Bank.

 

5.
            Community
Valley shall notify the Reserve Bank, in writing, no more than 30 days after
the end of any quarter in which any of the consolidated organization’s capital
ratios fall below the approved plan’s minimum ratios. Together with the
notification, Community Valley shall submit an acceptable capital plan that
details the steps Community Valley will take to increase the consolidated
organization’s capital ratios to or above the approved plan’s minimums.

 

Cash
Flow Projections

 

6.
            Within 30 days
of this Agreement, Community Valley shall submit to the Reserve Bank a written
statement of its planned sources and uses of cash for debt service, operating
expenses, and other purposes (“Cash Flow Projection”) for 2010. Community
Valley shall submit to the Reserve Bank a Cash Flow Projection for each
calendar year subsequent to 2010 at least one month prior to the beginning of
that calendar year.

 

 

Compliance
with Laws and Regulations

 

7.
            (a) In
appointing any new director or senior executive officer, or changing the
responsibilities of any senior executive officer so that the officer would
assume a different senior executive officer position, Community Valley shall
comply with the notice provisions of section 32 of the FDI Act (12 U.S.C. §
1831i) and Subpart H of Regulation Y of the Board of Governors (12 C.F.R. §§
225.71 et seq.).

 

(b)
Community Valley shall comply with the restrictions on indemnification and
severance payments of section 18(k) of the FDI Act (12 U.S.C. § 1828(k)) and
Part 359 of the FDIC’s regulations (12 C.F.R. Part 359).

 

Progress
Reports

 

8.
            Within 30 days
after the end of each calendar quarter following the date of this Agreement,
the board of directors shall submit to the Reserve Bank written progress reports
detailing the form and manner of all actions taken to secure compliance with
the provisions of this Agreement and the results thereof, and a parent company
only balance sheet, income statement, and, as applicable, report of changes in
stockholders’ equity.

 

Approval
and Implementation of Plan

 

9.
            (a)           Community Valley shall
submit a written capital plan that is acceptable to the Reserve Bank within the
applicable time period set forth in paragraph 4 of this Agreement. (b) Within
10 days of approval by the Reserve Bank, Community Valley shall adopt the
approved capital plan. Upon adoption, Community Valley shall promptly implement
the approved plan, and thereafter fully comply with it.

 

(c)
          During the term
of this Agreement, the approved capital plan shall not be amended or rescinded
without the prior written approval of the Reserve Bank.

 

Communications

 

10.
          All
communications regarding this Agreement shall be sent to:

 

	
  (a)
  

  	
  Mr.
  Ken Szyndel

  
	
   

  	
  Examining
  Manager

  
	
   

  	
  Banking
  Supervision & Regulation

  
	
   

  	
  Federal
  Reserve Bank of San Francisco

  
	
   

  	
  101
  Market Street, Stop 945

  
	
   

  	
  San
  Francisco, California 94105

  

 

 

	
  (b)

  	
  Mr.
  John F. Coger

  
	
   

  	
  President
  and Chief Executive Officer

  
	
   

  	
  Community
  Valley Bancorp

  
	
   

  	
  1360
  East Lassen Avenue

  
	
   

  	
  Chico,
  California 95973

  

 

Miscellaneous

 

11.
          Notwithstanding
any provision of this Agreement, the Reserve Bank may, in its sole discretion,
grant written extensions of time to Community Valley to comply with any
provision of this Agreement.

 

12.
          The provisions
of this Agreement shall be binding upon Community Valley and its
institution-affiliated parties, in their capacities as such, and their
successors and assigns.

 

13.
          Each provision
of this Agreement shall remain effective and enforceable until stayed,
modified, terminated, or suspended in writing by the Reserve Bank.

 

14.
          The provisions
of this Agreement shall not bar, estop, or otherwise prevent the Board of
Governors, the Reserve Bank, or any other federal or state agency from taking
any other action affecting Community Valley, the Bank, any nonbank subsidiary
of Community Valley, or any of their current or former institution-affiliated
parties and their successors and assigns.

 

15.
          Pursuant to
section 50 of the FDI Act (12 U.S.C. § 1831aa), this Agreement is enforceable
by the Board of Governors under section 8 of the FDI Act (12 U.S.C. § 1818).

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the
23rd day of July, 2010.

 

 

	
  COMMUNITY VALLEY BANCORP  

  	
   

  	
  FEDERAL
  RESERVE BANK OF SAN FRANCISCO 

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/
  John F. Coger

  	
   

  	
  By:
  

  	
  /s/
  Kenneth R. Binning

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  John F. Coger

  	
   

  	
  Kenneth
  R. Binning

  
	
  President/CEO

  	
   

  	
  Vice
  PresidentExhibit 10.1

 

** — CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
WITH RESPECT TO THE OMITTED PORTIONS.

 

2010 PFIZER EQUINE PRODUCTS MARKETING AGREEMENT

 

This
Agreement dated and effective as of January 1, 2010 is made by and between
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
(hereinafter, “PFIZER”) and MWI Veterinary Supply
Company, 651 South Stratford Drive, Suite 100, Meridian, ID
83642 (hereinafter, “MWI”).

 

1.                                       PFIZER hereby appoints MWI, and MWI hereby accepts appointment, as a
contract distributor for PFIZER Products set forth on Exhibit A (the “Products”), to purchase from PFIZER and to
resell for MWI’s own account as a distributor, subject to the following terms
and conditions.

 

2.                                       MWI recognizes and agrees to the following:

 

(a)                                  PFIZER has
elected to work with a select group of distributors that are committed to
maximizing the sale of the Products and to working closely with PFIZER to
identify market opportunities for both companies. The intent of this Agreement
is to attain that goal;

 

(b)                                 PFIZER intends
to utilize this group of distributors to sell the Products to customers below
them in the distribution chain and that PFIZER has, and may in the future, run
promotions and other activities that would be seriously prejudiced if MWI
resells the Products to other PFIZER contract distributors, non-employee agents
or through brokers.

 

3.                                       Accordingly, MWI shall:

 

(a)                                  use its
reasonable best efforts to sell the Products by focusing its primary effort at
reselling to veterinarians, OTC retailers, and horse owners;

 

(b)                                 maintain a
full-time outside and inside sales force that will personally and actively
solicit sales of the Products and pay such sales representatives reasonable
commission as MWI deems appropriate in its sole discretion;

 

(c)                                  store and
handle its inventory of Products under conditions that will ensure that such
Products retain their potency, purity, quality, and identity;

 

(d)                                 MWI will provide
PDA/EDI with sales out data on each PFIZER sku MWI sells. MWI will provide
to Covansys its Health Industry Number, Customer Health Industry Number, PFIZER
product number, transaction date, ship to zip code, number of units and price
with respect to each sale of product, and unit inventories on each PFIZER sku
that MWI sells. This information should be sent to Covansys. Sales out data
shall be provided to Covansys within /**/ of the date of each invoice. MWI will
use its best efforts to insure sales out data integrity and timeliness;

 

 

(e)                                  set its resale
prices for the Products independently and at its sole discretion;

 

(f)                                    cooperate fully
with PFIZER by actively participating in such strategy sessions as PFIZER
reasonably may require, for the purpose of developing programs to increase use
of the Products; and to cooperate fully with PFIZER in implementing all
promotions and sales campaigns for the Products;

 

(g)                                 allow PFIZER’s
representatives to attend and actively participate in meetings of MWI’s sales
representatives;

 

(h)                                 distribute the
Products only under the labeling provided by PFIZER; prescribe, recommend,
suggest, and advertise each Product for use only under the conditions stated in
the labeling provided by PFIZER; and observe all federal, state, and local laws
governing the distribution of animal drugs. In the case of Products bearing the
legend, “CAUTION: FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON THE ORDER OF
A LICENSED VETERINARIAN,” or any similar legend, sell such Products only to or
on the order of a licensed veterinarian for use in the course of his or her
professional practice or to another person or entity regularly and lawfully
engaged in the use, distribution or dispensing of such legend drugs;

 

(i)                                     MWI agrees that
credit limits established by PFIZER shall be subject to change by PFIZER in its
sole discretion and that no shipments will be made to MWI in excess of the
established credit limits;

 

(j)                                     take no action,
whether or not identified above, that would harm the goodwill or name of
PFIZER, or damage the interests of PFIZER or the Products, other than where
supported by sound factual evidence. For purposes of this Agreement “Goodwill”
shall mean the marketplace advantage of customer patronage and loyalty
developed with continuous business under the same name over a period of time;

 

(k)                                  MWI shall
immediately notify PFIZER in the event MWI obtains information indicating that
any of the Products may have to be recalled either by virtue of applicable law
or regulation or good business judgment. PFIZER shall control all efforts
necessary to conduct any such recall. MWI shall cooperate with PFIZER and MWI
agrees to maintain adequate records to conduct such recall, including the name,
address and Product purchases of all purchasers of PFIZER Products;

 

(l)                                     MWI may make
use of the Product Focus Funds provided for in Exhibit D hereto;

 

(m)                               Make payment to
PFIZER /**/; and

 

(n)                                 Provide to
PFIZER by the close of business on the last business day of each PFIZER
Accounting Period (as set forth in Exhibit E hereto) an inventory report
covering all inventory purchased from PFIZER and setting forth in dollars at
MWI’s acquisition cost from PFIZER the amount of inventory by species. MWI
agrees that PFIZER shall have the right to 

 

 

audit
inventory in the possession of MWI to confirm compliance with this
paragraph 3(n) and to confirm the accuracy of the data contained in
the report.

 

(o)                                 Each
distributor, veterinarian, dealer or producer must make its own independent
decision as to whether and how to sell and/or purchase Pfizer Animal Health’s
Equine products, including at what price to advertise, sell or value Pfizer
Animal Health’s Equine products. Notwithstanding the above, Pfizer may exclude
from rebate calculations any Pfizer Products sold by distributors,
veterinarians, dealers or producers below the recommended selling price.

 

4.                                       PFIZER shall:

 

(a)                                  sell the
Products to MWI at the prices in effect in the then current published PFIZER
Animal Health Products Distributor Price List (hereinafter, “Price List”). PFIZER also shall permit MWI to participate in
the distributor incentive programs offered by PFIZER, in accordance with the
terms of such programs. PFIZER shall have the unrestricted right to revise the
prices, terms and conditions of the Price List, and to add or delete Products
or package sizes, without advance notice to MWI, and the revisions shall be
effective on all orders submitted after the effective date of the price
revisions. In all cases of orders received for other than immediate shipment,
the price for the Products shall be that in effect at the time of shipment.
PFIZER agrees to give MWI /**/ advance notice of price increases;

 

(b)                                 compensate MWI
in accordance with Exhibits B, D and E hereto. In the event that one
Agreement holder acquires or combines with another Agreement holder, the
purchase objectives will be adjusted accordingly for the purpose of determining
incentives earned; and

 

(c)                                  allow MWI
credit on prepaid returns in accordance with PFIZER’s Outdated Products Policy
which is in effect at the time.

 

(d)                                 Agreement
holders with more than one location must combine purchases of all locations to
determine attainment level for incentives. In the event that one Agreement
holder acquires or combines with another Agreement holder, the purchase
objectives will be adjusted accordingly for the purpose of determining
incentives earned.

 

(e)                                  Direct purchase
from PFIZER will be used to determine the level of purchases achieved. Any
discrepancies must be documented by the Marketing Agreement holder using copies
of PFIZER invoices.

 

5.                                       Nothing in this Agreement shall be deemed to limit PFIZER’s ability to
sell Products to any other party.

 

6.                                       All purchases by MWI pursuant to this Agreement shall be in accordance
with the terms of PFIZER’s Pricing and Shipping Policies, as may be amended by
PFIZER from time to time. Unless the parties agree otherwise, shipments shall
be made to either MWI’s central warehouse point or to branch offices at MWI’s
direction.

 

 

7.                                       MWI shall not be provided with any rebate, discount or other compensation
for Products handled under this Agreement unless specifically set forth herein.
MWI will NOT be eligible to collect an RSA or Performance Payment on any
lateral sales to other PFIZER contract distributors or to an unauthorized
Pfizer distributor. (It is MWI’s obligation to confirm with Pfizer, prior to
making a sale, as to whether a distributor is a PFIZER contract distributor or
an unauthorized distributor.) Nor shall MWI be eligible to collect an RSA or
Performance Payment on sales made through brokers or non-employee agents.

 

8.                                       The following standard conditions shall apply to all sales under this
Agreement:

 

(a)                                  MWI shall
cooperate fully with PFIZER in participating fully in the Animal Health
Institute Electronic Data Interchange (“AHI EDI”) for
the reporting of sales and inventory data on a daily basis. The data to be
reported shall be as described in the AHI EDI Transaction sets.

 

(b)                                 all orders are
subject to acceptance by PFIZER’s New York Headquarters. Title to the goods
shall pass to MWI once they have been properly delivered to the address
designated by MWI. Products requiring temperature control will be shipped
F.O.B. destination;

 

(c)                                  any tax or
other charge upon the sale and/or shipment of the goods now or hereafter
imposed by federal, state or municipal authorities shall be paid by MWI. In the
event that the price of any article includes transportation charges, any
increase or decrease in transportation charges shall be for MWI’s account;

 

(d)                                 EXCEPT AS SET
FORTH IN THIS AGREEMENT, OR IN THE LABELING OF THE PRODUCTS SOLD HEREUNDER,
PFIZER MAKES NO EXPRESS OR IMPLIED WARRANTIES WITH RESPECT TO THE PRODUCTS;

 

(e)                                  PFIZER shall
defend and indemnify MWI from all claims resulting from any breach by PFIZER of
the warranties set forth in this paragraph 8, and specifically any claim
that the Products, as sold by PFIZER, were defective. In the event PFIZER is
found by any court of competent jurisdiction to be liable for any claim based
in products liability, then PFIZER shall reimburse MWI’s reasonable legal fees
incurred in the course of cooperating with PFIZER’s defense. To be covered by
this defense and indemnity, MWI must: promptly notify PFIZER of any such claim;
allow PFIZER to fully control the defense and/or resolution of the claim; and
cooperate fully with PFIZER in the matter. This defense, indemnity and payment
for legal fees shall not apply to claims alleging: MWI alteration, negligent
handling or improper storage of the Products; sale of outdated Products; sale
or recommendation of the Products for uses or in a manner not set forth in the
labeling supplied by PFIZER; or sale of the Products after receipt of notice
from PFIZER that such sales should be halted;

 

(f)                                    in no event
shall PFIZER be liable to MWI for special, collateral, incidental, or
consequential damages in connection with or arising out of the purchase,
resale, or use of the Products. Except as provided under
subparagraph 8(e), above, total damages recoverable against PFIZER by MWI
shall be exclusively limited to the purchase price of the Products with respect
to which damages are claimed;

 

 

(g)                                 failure of
PFIZER to make or of MWI to take, when due, any delivery (or portion thereof)
pursuant to an order hereunder, if occasioned by any circumstance or condition
beyond the control of the party so failing, shall not subject the failing party
to any liability to the other and, at the option of either party, that order or
portion thereof not delivered may be canceled;

 

(h)                                 acceptance of
MWI’s order by PFIZER is expressly made conditional upon MWI’s acceptance of
the conditions of sale as set forth herein, and the prices, terms and
conditions of the Price List then in effect, notwithstanding acknowledgment or
receipt of MWI’s purchase order containing additional or different provisions,
or conflicting oral representations by any agent of PFIZER.

 

9.                                       MWI shall not delegate its duty of performance or assign its obligations
under this Agreement without the prior written consent of PFIZER.

 

10.                                 MWI and PFIZER agree that, under the specific circumstances delineated
herein, PFIZER, at PFIZER’s sole discretion may recoup the sums outstanding to
it from MWI against those sums which may become due from PFIZER to MWI, in that
the obligations arise from mutual transactions. The specific circumstances
which will enable PFIZER to initiate recoupment are:

 

(a)                                  MWI becomes
insolvent which shall be defined as:

 

(i)                                     the sum of MWI’s
debts is greater than all of MWI’s property (“Balance
Sheet Test”); or

 

(ii)                                  MWI is generally
not paying its debts as they come due; or

 

(iii)                               MWI has failed
to act in good faith for a period in excess of six months to resolve any
outstanding invoice or purchase order issues or reconciliations.

 

(b)                                 MWI commences a
liquidation of its operations by means of a sale of its assets in their
entirety or piecemeal; or

 

(c)                                  MWI ceases its
business operations whether or not such cessation is voluntary or involuntary;
or

 

(d)                                 MWI files a
proceeding pursuant to the U.S. Bankruptcy Code or any state court proceeding,
including an Assignment for the Benefit of Creditors.

 

11.                                 This Agreement shall be effective as of the date first written above and
shall continue in force until December 31, 2010. Either party may
terminate this Agreement prior to the expiration date (i) with or without
cause, upon thirty (30) days written notice to the other party, or
(ii) immediately upon written notice, in the event of a material breach by
the other party.

 

12.                                 MWI and PFIZER acknowledge that in the performance of their duties
hereunder MWI and PFIZER may obtain access to “Confidential Information” (as
defined below) of each 

 

 

other. MWI and PFIZER agree that during the term of
this Agreement and for a period of five (5) years after the termination of
this Agreement, unless specifically permitted in writing by the other party,
which permission shall not be unreasonably withheld, especially in connection
with the sale of all or a substantial portion of MWI’s business, to
(a) retain in confidence and not disclose to any third party and
(b) use only for the purpose of carrying out their duties hereunder, any
such Confidential Information. As used herein the term “Confidential
Information” means any information, or data, whether of a business or
scientific nature and whether in written, oral or tangible form, relating to
PFIZER’s and MWI’s business or potential business or its research and
development activities, not generally available to or known to the public, and
not otherwise known to the receiving party, that is disclosed to or learned by
the other party pursuant hereto. “Confidential Information” does not mean or
include any information: (a) which is, at the time of disclosure,
available to the general public; or (b) which following disclosure becomes
available to the general public through no fault of the recipient; or
(c) which recipient can demonstrate was in its possession before receipt;
or (d) which is disclosed to recipient without restriction on disclosure.
Upon completion of the work provided for hereunder or other termination of this
Agreement each party will return to the other party any documents, or copies
thereof, or any product samples, containing or constituting Confidential
Information disclosed to or generated by either party in connection with this
Agreement. Neither MWI nor PFIZER shall disclose the existence of this
Agreement without the consent of the other party hereto.

 

13.                                 This Agreement shall be governed by the laws of the State of New York
applicable to contracts to be fully performed therein.

 

14.                                 This Agreement and documents referred to herein embody the entire
understanding between the parties hereto, will supersede prior agreements
relating to the Products, and may be modified only in writing and signed by the
parties to be bound. No activities conducted pursuant to this Agreement or
related thereto, including but not limited to the future planning activities of
the parties, shall be deemed to give rise to any obligations on the part of
either party other than as expressly provided for herein.

 

IN
WITNESS WHEREOF, intending to be legally bound, the parties have executed this
Agreement.

 

	
  MWI
  Veterinary Supply Company

  	
   

  	
  Pfizer
  Inc.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/
  Jim Cleary

  	
   

  	
  By:

  	
  /s/
  Clinton A. Lewis, Jr.

  
	
   

  	
   

  	
   

  	
   

  	
  Clinton
  A. Lewis, Jr.

  
	
  Print
  Name:

  	
  Jim
  Cleary

  	
   

  	
   

  	
  President,
  U.S. Operations

  
	
   

  	
   

  	
   

  	
   

  	
  Pfizer
  Animal Health

  
	
  Title:

  	
  President

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
  April
  29, 2010

  	
   

  	
  Date:

  	
  5/3/10

  

 

 

Exhibit A

 

Ethical Equine Distributor Product & RSA List

(Equine - LVSTK Distributor)

 

EFFECTIVE:    January 1, 2010 - December 31,
2010

 

	
  SKU #

  	
   

  	
  DESCRIPTION

  	
   

  	
  Rx

  	
   

  	
  UNIT

  	
   

  	
  Units/Ship

  per Min.

  Quantity

  	
   

  	
  RSA

  Eligible

  	
   

  	
  RSA %

  	
   

  	
  Performance

  Eligible

  
	
  ANTI-INFLAMMATORIES

  
	
  1424

  	
   

  	
  Depo-Medrol,
  40 mg/ml

  	
   

  	
   

  	
   

  	
  5ml

  	
   

  	
  24

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1425

  	
   

  	
  Depo-Medrol,
  20 mg/10 ml

  	
   

  	
  Rx

  	
   

  	
  10ml

  	
   

  	
  25

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1426

  	
   

  	
  Depo-Medrol,
  20 mg/20 ml

  	
   

  	
  Rx

  	
   

  	
  20ml

  	
   

  	
  24

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2187

  	
   

  	
  Domoso
  Gel

  	
   

  	
  Rx

  	
   

  	
  60 gm

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2188

  	
   

  	
  Domoso
  Gel

  	
   

  	
  Rx

  	
   

  	
  120 gm

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2189

  	
   

  	
  Domoso
  Solution

  	
   

  	
  Rx

  	
   

  	
  16 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2190

  	
   

  	
  Domoso
  Solution

  	
   

  	
  Rx

  	
   

  	
  Gallon

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2192

  	
   

  	
  Flucort
  Solution

  	
   

  	
  Rx

  	
   

  	
  100 ml

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1432

  	
   

  	
  Hylartin
  V

  	
   

  	
  Rx

  	
   

  	
  2 ml

  	
   

  	
  48

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2193

  	
   

  	
  Ketofen

  	
   

  	
  Rx

  	
   

  	
  50 ml

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2194

  	
   

  	
  Ketofen

  	
   

  	
  Rx

  	
   

  	
  100 ml

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1478

  	
   

  	
  Predef
  2X

  	
   

  	
  Rx

  	
   

  	
  100 ml

  	
   

  	
  6

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1489

  	
   

  	
  Solu-Delta
  Cortef, 100 mg

  	
   

  	
  Rx

  	
   

  	
  10 ml

  	
   

  	
  24

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1490

  	
   

  	
  Solu-Delta
  Cortef, 500 mg

  	
   

  	
  Rx

  	
   

  	
  10 ml

  	
   

  	
  24

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2209

  	
   

  	
  Torbugesic,
  10 mg

  	
   

  	
  CIV

  	
   

  	
  10 ml

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2210

  	
   

  	
  Torbugesic,
  10 mg

  	
   

  	
  CIV

  	
   

  	
  50 ml

  	
   

  	
   

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  ANTI-INFECTIVES

  
	
  1506

  	
   

  	
  Excede

  	
   

  	
  Rx

  	
   

  	
  200mg

  	
   

  	
  10

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1465

  	
   

  	
  Naxcel

  	
   

  	
  Rx

  	
   

  	
  1 gm

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1466

  	
   

  	
  Naxcel

  	
   

  	
  Rx

  	
   

  	
  4 gm

  	
   

  	
  6

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1463

  	
   

  	
  Sterile
  Water

  	
   

  	
   

  	
   

  	
  80 ml

  	
   

  	
  6

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1464

  	
   

  	
  Sterile
  Water

  	
   

  	
   

  	
   

  	
  20ml

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1519

  	
   

  	
  Tucoprim
  Powder

  	
   

  	
  Rx

  	
   

  	
  400 gm

  	
   

  	
  20

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1494

  	
   

  	
  Tucoprim
  Powder

  	
   

  	
  Rx

  	
   

  	
  2000 gm

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  ANTISEPTICS

  
	
  2198

  	
   

  	
  Nolvasan
  Suspension

  	
   

  	
   

  	
   

  	
  28 ml

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2055

  	
   

  	
  Nolvasan
  Solution

  	
   

  	
   

  	
   

  	
  Gallon

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2045

  	
   

  	
  Nolvasan
  Antiseptic Ointment

  	
   

  	
   

  	
   

  	
  7 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2046

  	
   

  	
  Nolvasan
  Antiseptic Ointment

  	
   

  	
   

  	
   

  	
  16 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2049

  	
   

  	
  Nolvasan
  S

  	
   

  	
   

  	
   

  	
  16 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2050

  	
   

  	
  Nolvasan
  S

  	
   

  	
   

  	
   

  	
  Gallon

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2051

  	
   

  	
  Nolvasan
  Shampoo

  	
   

  	
   

  	
   

  	
  8 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2052

  	
   

  	
  Nolvasan
  Shampoo

  	
   

  	
   

  	
   

  	
  Gallon

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2053

  	
   

  	
  Nolvasan
  Skin and Wound Cleanser

  	
   

  	
   

  	
   

  	
  4 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2054

  	
   

  	
  Nolvasan
  Skin and Wound Cleanser

  	
   

  	
   

  	
   

  	
  8 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2056

  	
   

  	
  Nolvasan
  Surgical Scrub

  	
   

  	
   

  	
   

  	
  16 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2057

  	
   

  	
  Nolvasan
  Surgical Scrub

  	
   

  	
   

  	
   

  	
  Gallon

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  

 

 

	
  SKU #

  	
   

  	
  DESCRIPTION

  	
   

  	
  Rx

  	
   

  	
  UNIT

  	
   

  	
  Units/Ship

  per Min.

  Quantity

  	
   

  	
  RSA

  Eligible

  	
   

  	
  RSA %

  	
   

  	
  Performance

  Eligible

  
	
  BIOLOGICALS (PER DOSE)

  
	
  2114

  	
   

  	
  Arvac
  Arteritis Vaccine

  	
   

  	
   

  	
   

  	
  10 x 1ds

  	
   

  	
  10

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2116

  	
   

  	
  Equiloid
  Innovator

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2117

  	
   

  	
  Equiloid
  Innovator

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2119

  	
   

  	
  Equivac
  Innovator EHV 1/4

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2120

  	
   

  	
  Fluvac
  Innovator

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2122

  	
   

  	
  Fluvac
  Innovator

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2139

  	
   

  	
  Fluvac
  Innovator EHV-4/1

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2141

  	
   

  	
  Fluvac
  Innovator EHV-4/1

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2123

  	
   

  	
  Fluvac
  Innovator 4

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2125

  	
   

  	
  Fluvac
  Innovator 4

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2128

  	
   

  	
  Fluvac
  Innovator 5

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2130

  	
   

  	
  Fluvac
  Innovator 5

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2134

  	
   

  	
  Fluvac
  Innovator 6

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2136

  	
   

  	
  Fluvac
  Innovator 6

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2146

  	
   

  	
  Fluvac
  Innovator Triple-E FT

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2147

  	
   

  	
  Fluvac
  Innovator Triple-E FT

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2151

  	
   

  	
  Pinnacle
  I.N.

  	
   

  	
   

  	
   

  	
  10 x 1ds

  	
   

  	
  10

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2153

  	
   

  	
  Pneumabort-K
  + 1 b

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2155

  	
   

  	
  Pneumabort-K
  + 1 b

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2156

  	
   

  	
  PotomacGuard

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2158

  	
   

  	
  PotomacGuard

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2159

  	
   

  	
  Rotovirus

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2160

  	
   

  	
  Tetanus
  Antitoxin

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2162

  	
   

  	
  Tetanus
  Antitoxin

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2164

  	
   

  	
  Tetanus
  Toxiod

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2166

  	
   

  	
  Tetanus
  Toxiod

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2167

  	
   

  	
  Triple-E
  T Innovator

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2169

  	
   

  	
  Triple-E
  T Innovator

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2184

  	
   

  	
  West
  Nile-Innovator DNA

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2181

  	
   

  	
  West
  Nile-Innovator

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2183

  	
   

  	
  West
  Nile-Innovator

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2172

  	
   

  	
  West
  Nile-Innovator + EW

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2173

  	
   

  	
  West
  Nile-Innovator + EWT

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2175

  	
   

  	
  West
  Nile-Innovator + EWT

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2177

  	
   

  	
  West
  Nile-Innovator + VEWT

  	
   

  	
   

  	
   

  	
  12 x 1ds

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2180

  	
   

  	
  West
  Nile-Innovator + VEWT

  	
   

  	
   

  	
   

  	
  10ds

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  5237

  	
   

  	
  Zylexis

  	
   

  	
  Rx

  	
   

  	
  5 x 1ds

  	
   

  	
  150

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  PARASITICIDES &
  INSECTICIDES

  
	
  6045

  	
   

  	
  Anthelcide
  EQ Paste

  	
   

  	
   

  	
   

  	
  Tube

  	
   

  	
  72

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  6056

  	
   

  	
  Anthelcide
  EQ Suspension

  	
   

  	
   

  	
   

  	
  Gallon

  	
   

  	
  4

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2200

  	
   

  	
  Quest
  Sure Dial, 11.6 gm

  	
   

  	
   

  	
   

  	
  Tube

  	
   

  	
  40

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2203

  	
   

  	
  Quest
  Plus Equine Oral Gel, 11.6 gm

  	
   

  	
   

  	
   

  	
  Tube

  	
   

  	
  40

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2204

  	
   

  	
  Quest
  Plus Equine Oral Gel, 11.6 gm

  	
   

  	
   

  	
   

  	
  Tube

  	
   

  	
  50

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2207

  	
   

  	
  Quest
  Bulk, 11.6 gm

  	
   

  	
   

  	
   

  	
  Tube

  	
   

  	
  50

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  8803

  	
   

  	
  Solitude
  IGR

  	
   

  	
   

  	
   

  	
  2 lb pail

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  8807

  	
   

  	
  Solitude
  IGR

  	
   

  	
   

  	
   

  	
  6 lb pail

  	
   

  	
  6

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  

 

 

	
  SKU #

  	
   

  	
  DESCRIPTION

  	
   

  	
  Rx

  	
   

  	
  UNIT

  	
   

  	
  Units/Ship

  per Min.

  Quantity

  	
   

  	
  RSA

  Eligible

  	
   

  	
  RSA %

  	
   

  	
  Performance

  Eligible

  
	
  8808

  	
   

  	
  Solitude
  IGR

  	
   

  	
   

  	
   

  	
  20 lb Pail

  	
   

  	
  2

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  7973

  	
   

  	
  Strongid
  Paste

  	
   

  	
   

  	
   

  	
  Tube

  	
   

  	
  72

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  7974

  	
   

  	
  Strongid
  Paste Bulk

  	
   

  	
   

  	
   

  	
  Tube

  	
   

  	
  96

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  7969

  	
   

  	
  Strongid
  C

  	
   

  	
   

  	
   

  	
  25 lb Pail

  	
   

  	
  36

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  7900

  	
   

  	
  Strongid
  C 2X

  	
   

  	
   

  	
   

  	
  10 lb Pail

  	
   

  	
  100

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  7866

  	
   

  	
  Strongid
  C 2X

  	
   

  	
   

  	
   

  	
  50 lb Bag

  	
   

  	
  10

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  7972

  	
   

  	
  Strongid
  T

  	
   

  	
  Rx

  	
   

  	
  Quart

  	
   

  	
  6

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  SEDATIVES &
  ANESTHESIA

  
	
  1419

  	
   

  	
  Carbocaine-V

  	
   

  	
  Rx

  	
   

  	
  50 ml

  	
   

  	
  100

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  6290

  	
   

  	
  Dormosedan

  	
   

  	
  Rx

  	
   

  	
  5 ml

  	
   

  	
  10

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  6292

  	
   

  	
  Dormosedan

  	
   

  	
  Rx

  	
   

  	
  20 ml

  	
   

  	
  10

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  SUPPLEMENTS

  
	
  2185

  	
   

  	
  Clovite
  Conditioner

  	
   

  	
   

  	
   

  	
  5 lb

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2186

  	
   

  	
  Clovite
  Conditioner

  	
   

  	
   

  	
   

  	
  25 lb

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  8047

  	
   

  	
  Lixotinic

  	
   

  	
   

  	
   

  	
  Gallon

  	
   

  	
  4

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2211

  	
   

  	
  V.A.L.
  Syrup

  	
   

  	
   

  	
   

  	
  Gallon

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  WOUND CARE

  
	
  8021

  	
   

  	
  Derma-Clens

  	
   

  	
   

  	
   

  	
  14 ounce

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  8252

  	
   

  	
  Granulex-V
  Aero Spray

  	
   

  	
   

  	
   

  	
  4 ounce

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  8253

  	
   

  	
  Granulex-V
  Liquid

  	
   

  	
   

  	
   

  	
  1 ounce

  	
   

  	
  12

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  REPRODUCTIVE PRODUCTS

  
	
  1455

  	
   

  	
  Lutalyse

  	
   

  	
  Rx

  	
   

  	
  30 ml

  	
   

  	
  96

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1504

  	
   

  	
  Lutalyse

  	
   

  	
  Rx

  	
   

  	
  100 ml

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  OTHER PRODUCTS

  
	
  2033

  	
   

  	
  Amiglyde
  V

  	
   

  	
  Rx

  	
   

  	
  48ml

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2191

  	
   

  	
  Equipoise

  	
   

  	
  CIII

  	
   

  	
  50 ml

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2195

  	
   

  	
  Kopertox

  	
   

  	
   

  	
   

  	
  8 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  2196

  	
   

  	
  Kopertox

  	
   

  	
   

  	
   

  	
  16 oz

  	
   

  	
  1

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  
	
  1487

  	
   

  	
  Roccal-D
  Plus

  	
   

  	
   

  	
   

  	
  Gallon

  	
   

  	
  4

  	
   

  	
  /**/

  	
   

  	
  /**/

  	
   

  	
  /**/

  

 

Terms
of All Equine Product Shipments:

1.               All orders must
exceed $250 for freight pre-paid.

2.               All orders will
be shipped in specified “Units/Shipper” quantities only.

3.               All orders will
receive standard terms.

4.               Prices are
subject to change without notice.

 

 

Exhibit B

 

PFIZER
shall compensate MWI in the following ways:

 

(a)           Reimburse MWI on a percentage of
sales out of Products as designated on the RSA product list contained in
Exhibit A, per the EDI sales out data calculated based on the products
purchase price contained in the Price List.

 

 

Exhibit C

 

Performance Payment

 

MWI
will be eligible to receive the performance payments set forth in this
clause 1 below subject to the performance criteria set forth below and MWI’s
fulfillment of all of the other obligations contained in this Agreement.

 

If
MWI has achieved sales out during the period January 1, 2010 through
December 31, 2010 of at least /**/of the Products listed below, MWI will
be eligible for a performance payment. The performance payment will be equal
to:

 

	
   

  	
  a)

  	
  $/**/plus

  
	
   

  	
  b)

  	
  /**/
  of all sales out between /**/ and /**/ plus

  
	
   

  	
  c)

  	
  /**/
  of sales out between /**/ and /**/ plus

  
	
   

  	
  d)

  	
  /**/
  of sales out between /**/ and /**/

  

 

Only
EDI data for invoices dated January 1, 2010 through December 31, 2010
and submitted to Covansys by December 31, 2010 and accepted by PFIZER from
Covansys by January 5, 2011 will count towards the calculation of sales
out for the period.

 

Only
sales by MWI of the products listed in Exhibit A count towards the
performance payments under this Exhibit C.

 

 

Exhibit D

 

Product Focus Funds

 

If
MWI fulfils all of the obligations set forth in this Exhibit D, PFIZER will
pay MWI up to a maximum of /**/ in Product Focus funds (“PFF”) based on MWI
executing PFF’s which are agreed with PFIZER. Programs that use these funds
must be discussed in advance with MWI’s PFIZER Account Executive, submitted in
writing to PFIZER’s Senior Director of Distribution and approved in writing by
PFIZER’s Senior Director of Distribution prior to the start of the program.
PFIZER shall have no obligation to pay MWI PFF’s if the parties are unable to
agree on the programs to be funded. In addition;

 

1.                                       To be eligible
for PFF’s, programs must include specific performance metrics and specifics on
total PFF’s to be spent in the program and how all PFF’s would be spent. In no
event will MWI be eligible to receive PFF’s in excess of /**/

 

2.                                       Programs that
result in a direct price decrease to the Purchaser will not be supported.

 

3.                                       ALL PFF’S
REQUIRE PROOF OF PERFORMANCE AT PROGRAM CONCLUSION. No payment of PFF’s will be
made by PFIZER to MWI until all proof or performance wrap-ups are submitted.

 

4.                                       All program
wrap-ups are to be submitted within forty-five (45) days of completion of the
program. Wrap ups for programs that run to year end 2010 should be submitted no
later than February 15, 2011 for payment. Any program wrap-ups submitted
to PFIZER after February 15, 2011 for 2010 programs will be paid of out
2011 PFF’s at PFIZER’s discretion. Programs will be paid by credit memo or
check.

 

 

Exhibit E

 

Pfizer Domestic 2010 Calendar

 

	
  Accounting
  Period

  	
   

  	
  Close Date

  	
   

  	
  # of Weeks

  	
   

  
	
  AP 1

  	
   

  	
  01/31/10

  	
   

  	
  4

  	
   

  
	
  AP 2

  	
   

  	
  02/28/10

  	
   

  	
  4

  	
   

  
	
  AP 3

  	
   

  	
  04/04/10

  	
   

  	
  5

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  AP 4

  	
   

  	
  05/02/10

  	
   

  	
  4

  	
   

  
	
  AP 5

  	
   

  	
  05/30/10

  	
   

  	
  4

  	
   

  
	
  AP 6

  	
   

  	
  07/04/10

  	
   

  	
  5

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  AP 7

  	
   

  	
  08/01/10

  	
   

  	
  4

  	
   

  
	
  AP 8

  	
   

  	
  08/29/10

  	
   

  	
  4

  	
   

  
	
  AP 9

  	
   

  	
  10/03/10

  	
   

  	
  5

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  AP 10

  	
   

  	
  10/31/10

  	
   

  	
  4

  	
   

  
	
  AP 11

  	
   

  	
  11/30/10

  	
   

  	
  5

  	
   

  
	
  AP 12

  	
   

  	
  12/31/10

  	
   

  	
  5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]